Navigation Links
Questcor to Commence Phase 2 Study of Acthar for ALS
Date:7/24/2013

l need such as ALS. Questcor also has agreed to acquire certain international rights for Synacthen® (tetracosactide) and Synacthen Depot®, and has licensed the right to develop and seek FDA approval for these products in the United States.  For more information about Questcor, please visit www.questcor.com.  For more information about Acthar, including important safety information, please visit www.acthar.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "believes," "continue," "could," "estimates," "expects," "growth," "intent," "may," "plans," "potential," "should," "substantial," "will," or "would" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:

  • Research and development risks, including risks associated with Questcor's work in the area of ALS;
  • Our reliance on Acthar for substantially all of our net sales and profits;
  • The lack of patent protection for Acthar; and the possible FDA approval and market introduction of competitive products;
  • The results of any pending or future litigation, investigations or claims, including with respect to the investigation by the United States Attorney's Office for the Eastern District of Pennsylvania regarding the Company's promotional practices and litigation brought by certain
    '/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Questcor to Report Second Quarter Financial Results on July 30, 2013
2. Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis
3. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
4. Questcor Adds Angus C. Russell to Board of Directors
5. Questcor Reports First Quarter Financial Results
6. Questcor to Report First Quarter Results on April 30, 2013
7. Questcor Reports Fourth Quarter and Full Year 2012 Results
8. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
9. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
10. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
11. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 Research ... of the "Inhaled Drug Delivery (London, UK - ... This Inhaled Drug Delivery meeting will cover industry ... and much more. The Co-Chairmen are Dr Steven ... , Senior Director, Mylan. Companies participating ...
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 ... the addition of the "An Introduction to ... - November 2-3, 2015)" conference to their ... a comprehensive introduction to the regulations and requirements ... will be highly interactive, using real life examples ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r6wspz/drug_delivery_in ) ... report "Drug Delivery in Central Nervous System ... their offering. Advances in understanding ... opened new avenues and possibilities for improved drug ... systems, enzymes, and receptors that control the penetration ...
Breaking Medicine Technology:An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3
... (Nasdaq:,CRYO), a medical device company focused on the treatment ... its pivotal,clinical study for the treatment of atrial fibrillation. ... said, "This is a,major milestone for CryoCor, being the ... for the use of ablation for the treatment of,atrial ...
... Novogen Limited,s subsidiary, Marshall Edwards Inc. (Nasdaq: MSHL ), has ... made the following ... Marshall Edwards, Inc. (Nasdaq: MSHL ) today announced enrolment of ... of,phenoxodiol in women with advanced ovarian cancer resistant or refractory,to platinum-based ...
Cached Medicine Technology:CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 2CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 3First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 2First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 3First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 4First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 5First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 6
(Date:9/3/2015)... ... 03, 2015 , ... B. E. Smith, the only full-service ... a national chief executive officer recruitment for Melissa Memorial Hospital in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:9/3/2015)... ... , ... Dr. Robert Winchell has been appointed director of the Trauma Center ... Cornell Medical Center, effective July 27. He will serve on the faculty of Weill ... the critically injured and the development, design and operations of trauma systems. As chief, ...
(Date:9/3/2015)... Angeles, Ca (PRWEB) , ... September 03, 2015 , ... ... is a promising and convenient test that may help patients with oropharyngeal cancer (oral ... cases in the United States are often caused by HPV infections, which have a ...
(Date:9/3/2015)... ... ... Global Vision , the world leader in the development of innovative ... artwork inspection solutions, ScanProof and ArtProof at Packaging Innovations 2015. , ... #F33 , Be the first to get a sneak peek of Intelligent Proofreading. Global ...
(Date:9/3/2015)... , ... September 03, 2015 , ... ... (ACA) triggering cost increases for fully insured employer-sponsored health insurance plans, more employers ... (1,000+ employees), according to data released from the 2014 United Benefit Advisors (UBA) ...
Breaking Medicine News(10 mins):Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4
... Ben-Gurion University of the Negev researcher has achieved a ... mouse cells. "This study may open new therapeutic ... pre-pubertal cancer patients at risk of infertility due to ... in adult patients," explains Prof. Mahmoud Huleihel, of BGU,s ...
... Training basic surgical techniques on toy animals before having to ... anxious. At the same time, the use of laboratory animals ... from LIFE - the Faculty of Life Sciences at the ... known as the ,teddy laboratory, strengthens learning and the teaching ...
... Amanda Gardner HealthDay Reporter , MONDAY, Nov. 14 ... of the brain seem to be involved in "chemo brain," ... treatments for breast cancer. According to research in the ... areas of the brain that are involved in planning, attention ...
... 15 (HealthDay News) -- Brainy children are at increased risk ... study says. Researchers analyzed data from nearly 8,000 people ... education and socioeconomic status. The participants, IQ scores were checked ... illegal drugs (marijuana, cocaine, uppers, downers, LSD and heroin) was ...
... Steven Reinberg HealthDay Reporter , TUESDAY, Nov. 15 ... to the statin drug Zocor (simvastatin) to help lower their ... Even though niacin appeared to increase HDL cholesterol -- ... fat in the blood, it did not reduce the risk ...
... breakthrough in understanding what stops a common form of skin ... available to the public in five years. ... Cancer Cell , an international team of scientists led ... University,s Department of Medicine at the Alfred Hospital, has discovered ...
Cached Medicine News:Health News:Surgery on toy animals lessens anxiety of veterinary students 2Health News:Breast Cancer Chemo Tied to Memory Troubles 2Health News:Breast Cancer Chemo Tied to Memory Troubles 3Health News:Smart Kids More Likely to Try Illicit Drugs as Young Adults 2Health News:No Benefit From Niacin for Heart Patients in Study 2Health News:No Benefit From Niacin for Heart Patients in Study 3Health News:Stop signal discovered for skin cancer 2
The Stat-Let lines of disposable lancets are all designed with the goals of providing a safe and easy to achieve capillary blood sampling. All of our lancets can be used by most current models of lan...
... flow while minimizing the pain ... the safety-engineered BD Microtainer Genie ... Lancet offers a full range ... capillary blood collection and protects ...
For patient-friendly and safe capillary blood collection...
... a widely used screening test for determining ... oriented Dispette branded system is considered the ... stamp. No other system meets defined NCCLS/ICSH ... care. Specialized systems are also available for ...
Medicine Products: